CompletedPhase 2NCT02997761

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brian Jonas
Principal Investigator
Brian Jonas
University of California, Davis
Intervention
Blinatumomab(biological)
Enrollment
19 enrolled
Eligibility
18 years · All sexes
Timeline
20172025

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Pharmacyclics LLC.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02997761 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials